30th September 2026, Wednesday

TechPharus

Latest Posts

HealthTech News

  • Atlas of immune cells explains how genetic variants cause disease
    on September 30, 2026 at 8:00 pm

    Scientists have identified thousands of genetic differences that change a person’s risk of disease, but working out how they actually affect biology—an important step toward creating new treatments—has been much more challenging. One reason is that many of the genetic variants associated with disease aren’t found in genes themselves, but within the vast stretches of DNA that regulate gene activity.

  • Insurance barriers limit access to blood cancer drugs
    on September 30, 2026 at 8:00 pm

    Patients with blood cancers often face major insurance hurdles and significant out-of-pocket costs when trying to access specialty oral anticancer medications, according to a new nationwide study led by researchers at the Perelman School of Medicine at the University of Pennsylvania.

  • Inhibitory brain cells balance memory detail and stability, study suggests
    on September 30, 2026 at 7:40 pm

    A team from the Plasticity of Brain Networks laboratory at the Institute for Neurosciences (IN), a joint center of the Spanish National Research Council (CSIC) and the University Miguel Hernández of Elche (UMH), has identified a mechanism that allows the brain to adjust the balance between two seemingly competing needs during memory formation: incorporating new details while maintaining representations that are sufficiently consistent to avoid confusing one experience with another.

  • Investigators identify a metabolic weak point in exhausted immune cells in head and neck cancer
    on September 30, 2026 at 7:40 pm

    Immune cells can reach head and neck tumors, but once there, many stop functioning. This helps explain why immunotherapy with immune checkpoint inhibitors—which have transformed treatment for some cancers—benefits only 17%–23% of patients with head and neck squamous cell carcinoma. These are cancers that arise from cells lining the mouth, throat and voice box.

  • Possible new target for sickle cell disease and beta thalassemia treatment identified
    on September 30, 2026 at 7:20 pm

    Harvard Medical School researchers at Boston Children’s Hospital and Dana-Farber Cancer Institute have identified a new pathway that regulates the production of fetal hemoglobin, a form of hemoglobin that normally gets replaced soon after birth by adult hemoglobin.